Yingkai Cheng

1.6k total citations · 1 hit paper
13 papers, 267 citations indexed

About

Yingkai Cheng is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Yingkai Cheng has authored 13 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Yingkai Cheng's work include Lung Cancer Treatments and Mutations (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and HER2/EGFR in Cancer Research (2 papers). Yingkai Cheng is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and HER2/EGFR in Cancer Research (2 papers). Yingkai Cheng collaborates with scholars based in United States, Japan and Spain. Yingkai Cheng's co-authors include Susan G. Sherman, Alex H. Kral, Sherie A. Dowsett, S. Hoog, Jose M. Pacheco, Andreas Saltos, Enriqueta Felip, Vinai Suriyanon, Zenta Tsuchihashi and Christina S. Baik and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Yingkai Cheng

12 papers receiving 261 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

2024 76 citations Egbert F. Smit, Enriqueta Felip et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yingkai Cheng United States	7	108	90	82	53	39	13	267
Davis T. Weaver United States	9	79 0.7×	167 1.9×	88 1.1×	43 0.8×	55 1.4×	14	361
Elena Clagnan Italy	10	82 0.8×	44 0.5×	53 0.6×	25 0.5×	33 0.8×	22	272
Anna‐Belle Beau France	12	81 0.8×	90 1.0×	62 0.8×	24 0.5×	61 1.6×	27	290
David Wolfson United States	8	40 0.4×	65 0.7×	39 0.5×	31 0.6×	21 0.5×	16	288
Janne C. Mewes Netherlands	11	49 0.5×	43 0.5×	157 1.9×	40 0.8×	54 1.4×	19	322
Efstathia Polychronopoulou United States	9	58 0.5×	37 0.4×	43 0.5×	33 0.6×	10 0.3×	32	242
Timmy Ho United States	10	64 0.6×	96 1.1×	37 0.5×	84 1.6×	108 2.8×	20	499
Lourdes García Puerto Rico	8	102 0.9×	35 0.4×	43 0.5×	25 0.5×	68 1.7×	15	257
Christopher M. Janson United States	11	118 1.1×	48 0.5×	24 0.3×	24 0.5×	88 2.3×	47	455
Yiyuan Wu United States	9	100 0.9×	22 0.2×	64 0.8×	77 1.5×	6 0.2×	32	368

Countries citing papers authored by Yingkai Cheng

Since Specialization

Citations

This map shows the geographic impact of Yingkai Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingkai Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingkai Cheng more than expected).

Fields of papers citing papers by Yingkai Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yingkai Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingkai Cheng. The network helps show where Yingkai Cheng may publish in the future.

Co-authorship network of co-authors of Yingkai Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Yingkai Cheng. A scholar is included among the top collaborators of Yingkai Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yingkai Cheng. Yingkai Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Contrepois, Kévin, Zenta Tsuchihashi, Kazuishi Kubota, et al.. (2025). Abstract 6364: Serum proteomics analysis: Potential biomarkers and mechanisms of trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis (ILD). Cancer Research. 85(8_Supplement_1). 6364–6364.

Tsuchihashi, Zenta, Kévin Contrepois, Kazuishi Kubota, et al.. (2025). Abstract 5928: Baseline serum protein analysis of patients with interstitial lung disease/pneumonitis (ILD) in 3 trastuzumab deruxtecan (T-DXd) trials: DESTINY-Breast01, DESTINY-Breast04, and DESTINY-Lung01. Cancer Research. 85(8_Supplement_1). 5928–5928. 1 indexed citations

Jänne, Pasi A., Toshio Kubo, Kiichiro Ninomiya, et al.. (2024). Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.. Journal of Clinical Oncology. 42(16_suppl). 8543–8543. 4 indexed citations

Smit, Egbert F., Enriqueta Felip, Dipesh Uprety, et al.. (2024). Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. The Lancet Oncology. 25(4). 439–454. 76 indexed citations breakdown →

Park, Yeonhee, Javier Cortés, Shanu Modi, et al.. (2024). Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies.. Journal of Clinical Oncology. 42(16_suppl). 12118–12118. 6 indexed citations

Krop, Ian E., Hans Wildiers, Sara A. Hurvitz, et al.. (2023). An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.. Journal of Clinical Oncology. 41(16_suppl). 1006–1006. 7 indexed citations

Michel, Alexander, Gabriel Chodick, Yingkai Cheng, et al.. (2018). Hypothyroidism in Young Children Following Exposure to Iodinated Contrast Media: An Observational Study and a Review of the Literature.. PubMed. 16(2). 256–265. 4 indexed citations

Jick, Susan S., Monique M. Hedderson, Fei Xu, et al.. (2018). Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States. Investigative Radiology. 54(5). 296–301. 15 indexed citations

Cheng, Yingkai, Xiquan Fu, & Yanfeng Bai. (2016). Impacts of cross-phase modulation on modulation instability of Airy pulses. Journal of Modern Optics. 63(19). 1917–1923. 2 indexed citations

10.

Ahl, Jonna, Mark E. Bangs, Yingkai Cheng, et al.. (2013). The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. Drug Healthcare and Patient Safety. 5. 211–211. 15 indexed citations

11.

Hoog, S., et al.. (2013). Duloxetine and Pregnancy Outcomes: Safety Surveillance Findings. International Journal of Medical Sciences. 10(4). 413–419. 27 indexed citations

12.

Sherman, Susan G., Yingkai Cheng, & Alex H. Kral. (2006). Prevalence and correlates of opiate overdose among young injection drug users in a large U.S. city. Drug and Alcohol Dependence. 88(2-3). 182–187. 70 indexed citations

13.

Cheng, Yingkai, Susan G. Sherman, Tasanai Vongchak, et al.. (2006). Risk factors associated with injection initiation among drug users in Northern Thailand. Harm Reduction Journal. 3(1). 10–10. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact